MLLT3 and acute myeloid leukemia: In an MLL-AF9-driven congenic AML mouse model, in vivo treatment with olcegepant reduced leukemic burden in BM and spleen, promoted myeloid differentiation, reduced the abundance and quiescence of an immuno-phenotypically defined LSC-enriched cell population [74], and decreased serial replating ability as a measure of LSC activity (AMG, unpublished results) (Figure 2).